Xaluritamig
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ewing Sarcoma
Conditions
Ewing Sarcoma
Trial Timeline
Apr 1, 2026 → May 26, 2030
NCT ID
NCT07297979About Xaluritamig
Xaluritamig is a phase 1 stage product being developed by Amgen for Ewing Sarcoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07297979. Target conditions include Ewing Sarcoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07297979 | Phase 1 | Recruiting |
| NCT06555796 | Phase 1 | Active |
Competing Products
14 competing products in Ewing Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Linsitinib | Astellas Pharma | Phase 2 | 52 |
| irinotecan liposome (II) + temozolomide + fluzoparib | Sun Pharmaceutical | Phase 2 | 52 |
| Abemaciclib + Irinotecan + Temozolomide | Eli Lilly | Phase 2 | 52 |
| IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) | Eli Lilly | Phase 2 | 52 |
| CP-751,871 | Pfizer | Phase 1 | 32 |
| CP-751,871 | Pfizer | Phase 1/2 | 40 |
| Palbociclib + Temozolomide + Irinotecan + Topotecan + Cyclophosphamide | Pfizer | Phase 2 | 51 |
| plerixafor + plerixafor + plerixafor | Sanofi | Phase 1/2 | 40 |
| regorafenib tablet | Bayer | Phase 1 | 30 |
| INCB059872 | Incyte | Phase 1 | 30 |
| Lurbinectedin | Jazz Pharmaceuticals | Phase 1/2 | 38 |
| Lurbinectedin | Jazz Pharmaceuticals | Phase 1/2 | 38 |
| Cabozantinib | Exelixis | Phase 1 | 30 |
| INBRX-109 + Irinotecan + Temozolomide + carboplatin + pemetrexed + Leucovorin + Fluorouracil | Inhibrx Biosciences | Phase 1 | 28 |